MeSH D009503 - neutropenia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Abbott Biotherapeutics | Amphotericin b | Amphotericin B | 1996-12-23 | |||
| AbbVie | Avibactam, Ceftazidime | Avycaz | 2026-01-07 | 2015-02-25 | ||
| Accord Healthcare | Filgrastim | Accofil | 2014-09-17 | |||
| Filgrastim | Grastofil | 2013-10-17 | ||||
| Itraconazole | Itraconazole | 2016-05-26 | ||||
| Pegfilgrastim | Pelgraz | 2018-09-21 | ||||
| Alembic Pharmaceuticals | Itraconazole | Itraconazole | 2016-12-13 | |||
| ALK-Abelló | Ciprofloxacin | Otiprio | 2029-04-21 | 2015-12-10 | ||
| Alkem Laboratories | Itraconazole | Itraconazole | 2017-06-12 | |||
| Vancomycin | Vancomycin | 2022-11-14 | ||||
| Alkopharma USA | Amphotericin b | Amphotec | 1996-11-22 | |||
| Allergan | Ciprofloxacin | Ciprofloxacin | 2005-01-21 | |||
| Vancomycin | Vancomycin | 2012-04-09 | ||||
| Altaire Pharmaceuticals | Ciprofloxacin | Ciprofloxacin | 2018-05-03 | |||
| Amgen | Pegfilgrastim | Neulasta | 2002-08-22 | $1,126 M | Y2022 | |
| Pegfilgrastim | Neulasta Onpro | 2002-01-31 | ||||
| Filgrastim | Neupogen | 1991-02-20 | $155 M | Y2013 | ||
| Pegfilgrastim | Ristempa | 2015-04-13 |
1
2
3
4
5
6
...
10
>
Clinical Trials
Historical Success Rate
Phase 1
67%26/39
Phase 2
48%27/56
Phase 3
48%26/54
Approved: 15Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
7
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use